Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Leukemia, Myeloid, Acute 198Leukemia, Lymphocytic, Chronic, B-Cell 48Myelodysplastic Syndromes 39Precursor Cell Lymphoblastic Leukemia-Lymphoma 32Recurrence 27Leukemia 26Lymphoma, Mantle-Cell 22Leukemia, Myelomonocytic, Chronic 16Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 15Leukemia, Biphenotypic, Acute 15Lymphoma, Follicular 14Lymphoma, Non-Hodgkin 12Lymphoma, Large B-Cell, Diffuse 12Lymphoma 12Burkitt Lymphoma 12Lymphoma, B-Cell, Marginal Zone 10Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Neoplasm, Residual 9Hematologic Neoplasms 9Multiple Myeloma 7Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 6Myeloproliferative Disorders 6Waldenstrom Macroglobulinemia 5Neoplasms 5Lymphoma, B-Cell 5Leukemia, Myeloid 5Blastic Plasmacytoid Dendritic Cell Neoplasm 5Leukemia, B-Cell 4Immunoglobulin Light-chain Amyloidosis 4Blast Crisis 4

Interventions

venetoclax 1fludarabine 1Melphalan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Venentoclax × venetoclax × Clear all
NCT07396480 2026-03-17

Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial

First Affiliated Hospital of Zhejiang University

Phase 3 Recruiting
186 enrolled
Other neoplasm

Venentoclax

Data powered by HemOnc (CC BY 4.0) Colophon âš¡